Reduction of breast density with 4-hydroxy tamoxifen

Details Reduction of breast density with 4-hydroxy tamoxifen Reduction of breast density with 4-hydroxy tamoxifen

2003-12-15

2009-02-03

Fetterolf, Brandon J (Department: 1642)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S561000, C424S449000, C424S488000

Reexamination Certificate

active

07485623

ABSTRACT:
A method of treatment comprises administering 4-hydroxy tamoxifen percutaneously to a patient having dense breast tissue. The 4-hydroxy tamoxifen may be formulated in a hydroalcoholic gel or an alcoholic solution.

REFERENCES:
patent: 4919937 (1990-04-01), Mauvais-Jarvis et al.
patent: 4973755 (1990-11-01), Grafe et al.
patent: 5045553 (1991-09-01), Ueda et al.
patent: 5613958 (1997-03-01), Kochinke et al.
patent: 5720963 (1998-02-01), Smith
patent: 5820877 (1998-10-01), Yamaguchi et al.
patent: 6013270 (2000-01-01), Hargraves et al.
patent: 6503894 (2003-01-01), Dudley et al.
patent: 2003/0087885 (2003-05-01), Masini-Eteve et al.
patent: 2004/0086552 (2004-05-01), Klokkers et al.
patent: 2005/0031695 (2005-02-01), Rouanet et al.
patent: 2005/0032909 (2005-02-01), Lignieres et al.
patent: 2005/0032910 (2005-02-01), Palumbo et al.
patent: 2005/0158388 (2005-07-01), Le Nestour et al.
patent: 2005/0208139 (2005-09-01), Hilt et al.
patent: 2005/0209340 (2005-09-01), Le Nestour
patent: 2006/0105041 (2006-05-01), Masini-Eteve
patent: 38 36 862 (1990-05-01), None
patent: 513 832 (1992-11-01), None
patent: WO 85/03228 (1985-08-01), None
patent: WO 95/24187 (1995-09-01), None
Brisson et al. (Cancer Epidemiology, Biomarkers & Prevention 2000; 9: 911-915).
Pujol et al. (Cancer Chemother. Pharmacol 1995; 36: 493-498).
Mauvais-Jarvis (Cancer Research 1986; 46: 1521-1525).
Atkinson et al. (Cancer Epidemiology, Biomarkers & Prevention 1999; 8: 863-866).
Boyd et al. (J. Nat. Cancer Inst. 1995; 87: 670-675).
Tan et al. (AAPS PharmSciTech 2000; 1; Article 24).
Alberti et al. (Journal of Controlled Release 2001; 71: 319-327).
Kolb et al. (Radiology 2002; 225; 165-175).
International Search Report.
F. Kuttenn et al., “Pricipe de l'adminstration percutanée des antiestrogènes en pathologie mammaire”, Contracept. Fertil. Sex., 1991, vol. 19, No. 2, pp. 165-171.
Catherine Malet et al., “Effect of 4-hydroxytamoxifen isomers on growth and ultrastructural aspects of normal human breast epithelial (HBE) cells in culture”, Journal of Steroid Biochemistry and Molecular Biology 82, (2002), pp. 289-296.
Charlotte Atkinson et al., “Mammographic Patterns as a Predictive Biomarker of Breast Cancer Risk: Effect of Tamoxifen”, Cancer Epidemiology, Biomarkers & Prevention, vol. 8, Oct. 1999, pp. 863-866.
J. Barrat et al., “Effet in vivo de l'administration locale de progestérone sur l'activité mitotique des galactophores humains”, J. Gynecol. Obstet. Biol. Reprod. 19: 269-274 1990.
N.F. Boyd et al., “Relationship Between Mammographic and Histological Risk Factors for Breast Cancer”, Journal of the National Cancer Institute. vol. 84, No. 15, Aug. 5, 1992, pp. 1170-1179.
N.F. Boyd et al., “Quantitative Classification of Mammographic Densities and Breast Cancer Risk: Results from the Canadian National Breast Screening Study”, Journal of the National Cancer Institute, vol. 87, No. 9, May 3, 1995, pp. 670-675.
Norman F. Boyd et al., “Effects at Two Years of a Low-Fat High-Carbohydrate Diet on Radiologic Features of the Breast: Results from a Randomized Trial”, Journal fo the National Cancer Institute, vol. 89, No. 7, Apr. 2, 1997, pp. 488-496.
Jacques Brisson et al., “Tamoxifen and Mammographic Breast Densities”, Cancer Epidemiology, Biomarkers & Prevention, vol. 9, Sep. 2000, pp. 911-915.
Celia Byrne, “Studing Mammographic Density: Implications for Understanding Breast Cancer”, Journal of the National Cancer Institute, vol. 89, No. 8, Apr. 16, 1997, pp. 531-537.
Philip Carthew et al., “Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat”, Arch Toxicol (2001) 75: 375-380.
Gerard Chetrite et al., “Effect of Promegestone, Tamoxifen, 4-Hydroxytamoxifen and ICI 164,384 on the Oestrone Sulphatase Activity of Human Breast Cancer Cells”, Anticancer Research 13: 931-934 (1993).
Eric C. Dietze et al., “Tamoxifen but Not 4-Hydroxytamoxifen Initiates Apoptosis in p53(-) Normal Human Mammary Epithelial Cells by Inducing Mitochondrial Depolarization”, The Journal of Biological Chemistry vol. 276, No. 7, Issue of Feb. 16, 2001, pp. 5384-5394.
Laurie L. Fajardo MD et al., “Correlation Between Breast Parenchymal Patterns and Mammographers' Certainty of Diagnosis”, Investigative Radiology, vol. 23, No. 7,. Jul. 1988, pp. 505-508.
Ian S. Fentiman, “Tamoxifen and Mastalgia an Emerging Indication”, Drugs, vol. 32, No. 6, Dec. 1986, pp. 477-480.
I.S. Fentiman et al., “Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial”, Br. J. Surg. Sep. 1988, vol. 75, No. 9, pp. 845-846.
I.S. Fentiman et al., “Studies of tamoxifen in women with mastalgia*”, The British Journal of Clinical Practice, Supplement 68, vol. 43, No. 11, Nov. 1989, pp. 34-36.
N. Giambiagi et al., “Immunological Differences Between the Estradiol-, Tamxifen- and 4-Hydroxy-Tamoxifen-Estrogen Receptor Complexes Detected by Two Monoclonal Antibodies”, J. Steroid Biochem. vol. 30, No. 1-6, pp. 213-217, 1988.
Susan C. Harvey et al., “Marked Regression of a Nonpalpable Breast Cancer After Cessation of Hormone Replacement Therapy”, American Journal of Roentgenology, Aug. 1996, 167: 394-395.
Jennifer A. Harvey et al., “Short-term Cessation of Hormone Replacement Therapy and Improvement of Mammographic Specificity”, Journal of the National Cancer Institute, vol. 89, No. 21. Nov. 5, 1997, pp. 1623-1625.
IBIS investigators, “First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial”, The Lancet, vol. 360, Sep. 14, 2002, pp. 817-824.
Susan Jenks, “Dense Breast Tissues May Hold Increased Cancer Risk for Some”, Journal of the National Cancer Institute, vol. 86, No. 8, Apr. 20, 1994, pp. 578-580.
V. Craig Jordan et al., “Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance”, Breast Cancer Research and Treatment, 2, pp. 123-138, 1982.
Karla Kerlikowske MD et al., “Effect of Age, Breast Density, and Family History on the Sensitivity of First Screening Mammography”, JAMA, vol. 276, No. 1, Jul. 3, 1996, pp. 33-38.
Z. Kaufman et al., “The Mammographic Parenchymal Patterns of Women on Hormonal Replacement Therapy”, Clinical Radiology (1991), 43, 389-392.
Thomas M. Kolb MD et al., “Comparison of the Performance of Screening Mammography, Physical Examination, and Breast US and Evaluation of Factors that Influence Them: An Analysis of 27,825 Patient Evaluations”, Radiology, vol. 225, No. 1, Oct. 2002, pp. 165-175.
George G.J.M. Kuiper et al., “Comparision of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors α and β”, Endocrinology, vol. 138, No. 3, 1997, pp. 863-870.
Frédérique Kuttenn et al., “Médecine et Thérapeutique”, C.R. Acad. Sc. Paris , , Série III, No. 12, 1985, 300:457-461.
Winnie Leung MD et al., “Mammographic density in women on postmenopausal hormone replacement therapy”, Surgery, vol. 122, No. 4, Oct. 1997, pp. 669-674.
L. Ma et al., “Case-Control Study of Factors Associated With Failure to Detect Breast Cancer by Mammography”, Journal of the National Cancer Institute, vol. 84, No. 10, May 20, 1992, pp. 781-784.
Catherine Malet et al., “Tamoxifen and Hydroxytamoxifen Isomers versus Estradiol Effects on Normal Human Breast Cells in Culture”, Cancer Research, vol. 48, No. 24, Dec. 15, 1988, pp. 7193-7199.
Pierre Mauvais-Jarvis et al., “trans-4-Hydroxytamoxifen Concentration and Metabolism after Local Percutaneous Administration to Human Breast”, Cancer Research, vol. 46, Mar. 1986, pp. 1521-1525.
Henri Pujol et al., “Phase I Study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentr

Affiliated with

Also associated with

Rating

Reduction of breast density with 4-hydroxy tamoxifen does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Reduction of breast density with 4-hydroxy tamoxifen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reduction of breast density with 4-hydroxy tamoxifen will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4117206